Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib plus erlotinib versus placebo plus erlotinib in advanced or metastatic non-small cell lung cancer
NL-OMON33771Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of sunitinib and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoint: Overall survival. Started Oct 2007; status: active, not recruiting.
02
Drugs
sunitiniberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON33771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33771.